57
Participants
Start Date
March 31, 2016
Primary Completion Date
December 31, 2020
Study Completion Date
December 31, 2020
Sym015
Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.
Rigshospitalet, Copenhagen
Taipei Medical University Hospital, Taipei
Tri-Service General Hospital, Taipei
CHA Bundang Medical Center, CHA University, Seongnam-si
Centro Oncologico MD Anderson, Madrid
China Medical University Hospital, Taichung
Taichung Veterans General Hospital, Taichung
University Hospitals Cleveland Medical Center, Cleveland
Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis
University of Chicago Medical Center, Chicago
National Cheng Kung University Hospital, Tainan City
University of Texas Southwestern Medical Center, Dallas
The University of Texas M.D. Anderson Cancer Center, Houston
South Texas Accelerated Research Therapeutics, LLC, San Antonio
University of Colorado Cancer Center, Aurora
Comprehensive Cancer Centers of Nevada, Las Vegas
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute/D -1251, Boston
Queen Mary Hospital, Hong Kong
Severance Hospital, Yonsei University Health System, Seoul
Asan Medical Center, Seoul
Gangnam Severance Hospital, Yonsei University Health System, Seoul
Samsung Medical Center, Seoul
Korea University Guro Hospital, Seoul
Hospital Universitario Quiron Dexeus, Barcelona
Hospital Universitario Vall d'Hebron, Barcelona
Hospital Clinic de Barcelona, Barcelona
Symphogen A/S
INDUSTRY